Reversed-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-08. Numbers and descriptions here follow the published literature rather than marketing material.
Dissolution is usually performed in water or a suitable aqueous buffer, and the resulting liquid is divided into single-use portions before freezing. Freeze-thaw cycling is a recognised source of loss for short peptides, since each cycle can encourage aggregation or adsorption onto container walls. Working solutions are generally kept cold and used within a short window, although published stability data specific to epitalon are thin. Containers should be marked with concentration and date, and solutions examined for cloudiness before use.
Identity is normally established by reversed-phase high-performance liquid chromatography combined with mass spectrometry, a pairing that separates components and confirms molecular mass at once. Purity is quoted as a percentage from the chromatogram, and figures above ninety-five percent are a frequent commercial specification. Amino acid analysis or sequencing supplies further confirmation when required. Because many short peptides behave similarly under chromatography, retention time alone does not establish sequence; the mass measurement is what separates one tetrapeptide from another, and certificates should report both.
In its supplied form epitalon is a white to off-white powder, usually lyophilized and often hygroscopic. It dissolves readily in water and in aqueous buffers, and it is commonly handled as the acetate or trifluoroacetate salt to improve stability during purification and drying. The amide backbone is labile in aqueous media, so solutions are less durable than the dry solid. Handling notes in the chemical literature therefore emphasize keeping the powder dry, cool and shielded from light until it is dissolved.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
| Property | Value | Notes |
|---|---|---|
| Sequence | Ala-Glu-Asp-Gly | Written in three-letter amino acid code |
| Single-letter code | AEDG | Form used in most catalogue entries |
| Typical purity specification | 95 percent or higher | Value read from the HPLC chromatogram |
| Storage, dry solid | Minus 20 degrees Celsius, desiccated | Sealed container, protected from light |
| Handling, solution | Divide into single-use portions | Limits losses from freeze-thaw cycling |
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.
Material supplied for laboratory use is normally a lyophilised white to off-white powder that dissolves readily in water and in isotonic saline. Lyophilised cakes are hygroscopic and should be equilibrated to room temperature before opening to limit condensation on the solid. Solutions are typically prepared at milligram-per-millilitre concentrations and divided into single-use aliquots, because repeated freeze–thaw cycles degrade short peptides. Aqueous solutions are far less stable than the dry powder, and identity is usually verified by mass spectrometry alongside purity estimation from reversed-phase high-performance liquid chromatography.
Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.
Freeze-dried epitalon is normally kept at minus twenty degrees Celsius in a sealed, desiccated container, protected from light. Short excursions at ambient temperature during shipping are generally tolerated, but repeated warming and cooling cycles encourage moisture uptake, which shortens shelf life. Once dissolved, the peptide is far less stable than the solid: aqueous solutions are subject to hydrolysis and to deamidation at the aspartate and glutamate residues. Working solutions are therefore held refrigerated and used within days, and repeated freezing and thawing of the same vial is best avoided.
Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.
== History == Although many authors had suggested the use of power formulas in sediment transport in the decades preceding Bagnold's work, and in fact Bagnold himself suggested it a decade before putting it into practice in one of his other works, it wasn't until 1966 that R. A. Bagnold tested this theory experimentally to validate whether it would indeed work or not. This was successful and since then, many variations and applications of stream power have surfaced. The lack of fixed guidelines on how to define stream power in this early stage lead to many authors publishing work under the name "stream power" while not always measuring the entity in the same way; this led to partially failed efforts to establish naming conventions for the various forms of the formula by Rhoads two decades later in 1986. Today stream power is still used and new ways of applying it are still being discovered and researched, with a large integration into modern numerical models utilizing computer simulations.
== Regulatory pathways via fuzzy regions == Fuzzy regions modulate the conformational equilibrium or flexibility of the binding interface via transient interactions. Dynamic regions can also compete with binding sites or tether them to the target. Modifications of fuzzy regions by further interactions, or posttranslational modifications impact binding affinity or specificity. Alternative splicing can modulate the length of fuzzy regions resulting in context-dependent binding (e.g. tissue-specificity) on the complex. EGF/MAPK, TGF-β and WNT/Wingless signaling pathways employ tissue-specific fuzzy regions.
Although nilutamide has been found to be effective for transgender hormone therapy, the use of nilutamide in the treatment of prostate cancer, and particularly for other indications that are of a less clinically serious nature, is now discouraged due to the unique adverse effects of the medication, most importantly a high incidence of interstitial pneumonitis. This is an adverse effect that can progress to pulmonary fibrosis and can potentially be fatal. Flutamide is also no longer recommended due to excessive risk of hepatotoxicity and liver failure in men with prostate cancer. For these reasons, newer and safer NSAAs like bicalutamide have largely replaced flutamide and nilutamide, and are now used for relevant indications instead. As selective AR antagonists, flutamide, nilutamide, and bicalutamide have the same mechanism of action, and bicalutamide has similar or greater efficacy to flutamide and nilutamide as an antiandrogen. Bicalutamide is known to have a small risk of elevated liver enzymes and serious liver toxicity. As a result, it is recommended that liver function tests (LFTs) periodically be performed. One protocol that has been recommended is to check LFTs at baseline, at one month, at two months, and then every 6 months thereafter. The risk of elevated liver enzymes and liver failure with bicalutamide appears to be much smaller than with high doses of CPA, which is the most widely used antiandrogen in transgender women in Europe and elsewhere in the world. However, only low doses of CPA are now recommended for use in transgender women.
Second Cup agreed to transform some of its western Canada locations into recreational cannabis dispensaries, with no cannabis-related products to be sold at its cafés. The company stated that this alliance would allow it to leverage its real estate assets to drive value for the franchisees without affecting plans for new product innovation and opening new cafés across Canada. In August 2018, the company was already considering which of its locations in Ontario might be suitable as cannabis retail stores as an alternative to their current use, in conjunction with National Access Cannabis. On November 8, 2019, Second Cup announced plans to change its name to Aegis Brands Inc. (TSX: AEG), pending stockholder approval the following year. The company was scheduled to open two cannabis stores in Calgary in early 2020 and planned expansion into Ontario. On December 5, 2019, Aegis Brands announced its acquisition of Ottawa-based coffeehouse chain Bridgehead Coffee for $11 million. In February 2021, Aegis Brands agreed to sell Second Cup to Quebec-based Foodtastic Inc. for an undisclosed sale price that included $14 million in cash. Foodtastic chief executive Peter Mammas said that the company intended to expand the brand to 300 locations by 2025, from the existing store count of 190. In May 2025, Second Cup's international division filed for creditor protection under the Companies' Creditors Arrangement Act in Canada. This comes after the company was unable to pay nearly $10 million to its creditors.
==== Site shaving ==== Before branding, the site of the brand must be shaved very closely to the skin. The site should also be shaved with at least the bottom edge as square as possible. This assists the worker when placing the brand and helps prevent it from dislodging on animals with thick coats. The excellent insulating properties of hair make a close shave critically important for achieving an even brand. Shaving permits a close interface between brand and flesh. Specialized clipper blades and heads have been designed for cryogenic branding and are made to provide as close a shave as possible. Once shaved, the area to be branded is soaked with alcohol to disinfect the animal's skin.
Sources: en.wikipedia.org
Any single cycle is longer than 90 days, as long as the individual is at least one year post menarche. The cycle is generally shorter than 21 days or longer than 45 days, as long as the individual is at least one year post menarche. The cycle is generally longer than 35 days, as long as the individual is at least three years post menarche. Amenorrhea which is not due to another underlying cause, as long as the individual is at least 15 years old or at least 3 years post thelarche. Biochemical androgen excess in PMOS is assessed using total and free testosterone. Accurate measurement requires tandem mass spectrometry assays, as direct free testosterone tests are not reliable. Interpretation is based on laboratory reference ranges. Hormonal contraception can interfere with hormone levels, so a withdrawal period of at least three months with alternative contraception may be needed. Severely elevated androgen levels may indicate other conditions.
Little prolactin—the predominant form. It has a molecular weight of approximately 23-kDa. It is a single-chain polypeptide of 199 amino acids and is apparently the result of removal of some amino acids. Big prolactin—approximately 48 kDa. It may be the product of interaction of several prolactin molecules. It appears to have little, if any, biological activity. Macroprolactin—approximately 150 kDa. It appears to have a low biological activity. Other variants with the molecular masses of 14, 16, and 22 kDa. The levels of larger ones are somewhat higher during the early postpartum period.
== Process == The first step of the PEGylation is the suitable functionalization of the PEG polymer at one or both ends. PEGs that are activated at each end with the same reactive moiety are known as "homobifunctional", whereas if the functional groups present are different, then the PEG derivative is referred as "heterobifunctional" or "heterofunctional". The chemically active or activated derivatives of the PEG polymer are prepared to attach the PEG to the desired molecule. The overall PEGylation processes used to date for protein conjugation can be broadly classified into two types, namely a solution phase batch process and an on-column fed-batch process. The simple and commonly adopted batch process involves the mixing of reagents together in a suitable buffer solution, preferably at a temperature between 4 and 6 °C, followed by the separation and purification of the desired product using a suitable technique based on its physicochemical properties, including size exclusion chromatography (SEC), ion exchange chromatography (IEX), hydrophobic interaction chromatography (HIC) and membranes or aqueous two-phase systems (ATPS). The choice of the suitable functional group for the PEG derivative is based on the type of available reactive group on the molecule that will be coupled to the PEG. For proteins, typical reactive amino acids include lysine, cysteine, histidine, arginine, aspartic acid, glutamic acid, serine, threonine and tyrosine.
=== Local helium spray === This method is a small variation from the one above. It still requires the part to be tested to be connected to a helium leak detector and all steps above and vacuum pump sizing based on the part size are followed. However, the outer surface of the part to be tested is sprayed with a localized stream of helium tracer gas where the spray head will be moved across the part. Thus, correlation between maximum leakage signal and helium spray head location will allow the operator to pinpoint the leaky area for possible repair or further investigation.
As a result of its weak intrinsic androgenicity, CPA may not be as effective in the treatment of certain androgen-sensitive conditions such as prostate cancer compared to nonsteroidal antiandrogens with a silent antagonist profile at the AR. Indeed, CPA has never been found to extend life in prostate cancer patients when added to castration relative to castration alone, unlike nonsteroidal antiandrogens. As such, it is thought that the partial androgenic activity of CPA and other steroidal antiandrogens underlies the superior antiandrogenic efficacy of silent-antagonist nonsteroidal antiandrogens like flutamide. However, the clinical significance of the weak androgenic activity of CPA has also been disputed. In fact, some studies have found little or no stimulating effect of CPA on the prostate gland or seminal vesicles of male rats even with very high circulating concentrations of CPA. Nonsteroidal antiandrogens like flutamide and bicalutamide are more efficacious as antiandrogens than CPA in castrated animals due to their superior AR antagonistic activity. Conversely, CPA is a much more potent antiandrogen than nonsteroidal antiandrogens like flutamide and bicalutamide in gonadally intact male animals, which is due to its antigonadotropic effects and consequent suppression of testosterone levels (nonsteroidal antiandrogens do not suppress testosterone levels). CPA at high doses (e.g., 25–50 mg/day) has been reported to suppress SHBG levels, and may have a partial androgenic effect on hepatic SHBG production at such doses.
Sources: en.wikipedia.org
=== Articles === Wadden, TA; Stunkard, AJ (1985). "The psychological and social consequences of obesity". Annals of Internal Medicine. 103 (6 ( Pt 2)): 1062–1067. doi:10.7326/0003-4819-103-6-1062. PMID 4062126. Wadden, TA; Bailey, TS; Billings, LK (2021). "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial". JAMA. 325 (14): 1403–1413. doi:10.1001/jama.2021.1831. PMC 7905697. PMID 33625476. Wadden, TA; Berkowitz, RI; Womble, LG (2005). "Randomized trial of lifestyle modification and pharmacotherapy for obesity". The New England Journal of Medicine. 353 (20): 2111–2120. doi:10.1056/NEJMoa050156. PMID 16291981. Wadden, TA; Webb, VL; Moran, CH; Bailer, BA (2012). "Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy". Circulation. 125 (9): 1157–1170. doi:10.1161/CIRCULATIONAHA.111.039453. PMC 3313649. PMID 22392863. Heymsfield, SB; Wadden, TA (2017). "Mechanisms, pathophysiology, and management of obesity". The New England Journal of Medicine. 376 (3): 254–266. doi:10.1056/NEJMra1514009. PMID 28099824. Wadden, Thomas A.; Tronieri, Jena S.; Butryn, Meghan L. (2020). "Lifestyle modification approaches for the treatment of obesity in adults". American Psychologist. 75 (2): 235–251. doi:10.1037/amp0000517. PMC 7027681. PMID 32052997.
On the other hand, many of the potentials used in physics, such as those based on the bond order formalism can describe several different coordinations of a system and bond breaking. Examples of such potentials include the Brenner potential for hydrocarbons and its further developments for the C-Si-H and C-O-H systems. The ReaxFF potential can be considered a fully reactive hybrid between bond order potentials and chemistry force fields.
HTT is expressed in all cells, with the highest concentrations found in the brain and testes, and moderate amounts in the liver, heart, and lungs. Although its full range of functions is not yet understood, HTT interacts with proteins involved in transcription, cell signaling, and intracellular transport. Studies in genetically modified animals have shown that wild-type HTT is essential for embryonic development, as complete absence of the gene results in embryonic death. HTT also plays a protective role in mature neurons: it regulates the production of brain-derived neurotrophic factor, supports synaptic vesicular transport and synaptic transmission, controls neuronal gene transcription, and prevents programmed cell death by inhibiting apoptotic enzymes such as caspases. In contrast to these protective roles, the mutant form of the protein (mHTT) interferes with the ubiquitin-proteasome system, which promotes caspase activation, contributing to neurodegeneration. Increasing the expression of HTT can promote brain cell survival and ameliorate the effects of mHTT, whereas reducing it can exacerbate those effects. Accordingly, the disease is thought not to be caused by inadequate expression of HTT, but by a toxic gain-of-function of mHTT in the body. The mutant protein is expressed throughout the body and associated with abnormalities in peripheral tissues outside of the brain, which can include muscle atrophy, cardiac failure, impaired glucose tolerance, weight loss, osteoporosis, and testicular atrophy.
==== Differentiation of scars ==== While scars are associated with the desmoplastic response of various cancers, not all scars are associated with malignant neoplasms. Mature scars are usually thick, collagenous bundles arranged horizontally with paucicellularity, vertical blood vessels, and no appendages. This is distinguished from desmoplasia in the organization of the tissue, the appendages, and orientation of blood vessels. Immature scars are more difficult to distinguish due to their neoplastic origins. These scars are hypercellular with fibroblasts, myofibroblasts, and some immune cells present. The immature scars can be distinguished from desmoplasia by immunohistochemical staining of biopsied tumors that will reveal the type and organization of cells present as well as whether recent trauma has occurred to the tissue.
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography is run alongside mass spectrometry. The chromatogram separates components and gives a purity figure, while the mass spectrum confirms that the measured molecular mass matches the expected sequence. Neither measurement on its own is treated as sufficient.
Long-term holding is usually at minus twenty degrees Celsius in a sealed, desiccated container. A refrigerator is adequate for short intervals before use. Light exposure is normally avoided as well. Allowing a cold container to warm before opening reduces moisture condensation on the contents.
Repeated cycles are generally avoided. Each freeze and thaw can promote aggregation or loss of peptide to container surfaces, which reduces the amount available for later work. Dividing a solution into single-use portions at the outset is the usual way to limit this problem.
The peptide contains four residues in the order alanine, glutamate, aspartate and glycine, abbreviated AEDG. The chain is linear and held together by three peptide bonds. Its calculated mass for the uncharged free form is about 390.3 daltons.